健帆生物：上半年公司销售费用为24961万元，同比减少26.75%

Core Viewpoint - The company has reported a significant reduction in sales expenses and is adjusting the pricing of its blood perfusion device in response to new healthcare policies in China [1] Group 1: Sales Expenses - In the first half of 2025, the company's sales expenses amounted to 24.961 million yuan, representing a year-on-year decrease of 26.75% [1] Group 2: Policy Impact - The National Healthcare Security Administration issued a guideline in June this year, adding "blood dialysis perfusion fee" and "plasma adsorption fee" as new items, which have been officially included in the medical insurance projects with independent pricing standards [1] - Over twenty provinces in China are actively implementing these policies, which are expected to drive growth in the clinical use of blood perfusion and adsorption products [1] Group 3: Pricing Adjustment - Starting from September 2025, the company will adjust the price of its KHA130 blood perfusion device, which is specifically used for maintenance hemodialysis patients, as part of its commitment to social responsibility and patient care [1]